⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for acute myeloid leukemia

Every month we try and update this database with for acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction TherapyNCT00728520
Acute Myeloid L...
Elderly
Azacitidine
60 Years - Kansas City Veteran Affairs Medical Center
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) PatientsNCT00952588
Acute Myeloid L...
AZD1152
LDAC
60 Years - AstraZeneca
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesNCT03465540
Multiple Myelom...
Acute Myeloid L...
Non-Hodgkins Ly...
Myelodysplastic...
AML
MDS
NHL
AMG 397
Dexamethasone
Azacitidine
18 Years - 65 YearsAmgen
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual DiseaseNCT04209712
Acute Myeloid L...
haploid allogen...
1 Year - 80 YearsShanghai iCELL Biotechnology Co., Ltd, Shanghai, China
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)NCT02842827
Acute Myeloid L...
Myelodysplastic...
bomedemstat
tretinoin
18 Years - Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or LymphomaNCT04460235
Vaccine
Streptococcus P...
Acute Myeloid L...
Lymphoma, Non-H...
Prevenar13 Pneu...
18 Years - Poitiers University Hospital
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeNCT01636609
Acute Myeloid L...
High Risk Myelo...
Azacitidine
Cytarabine
Tosedostat
60 Years - M.D. Anderson Cancer Center
TL-895 and KRT-232 Study in Acute Myeloid LeukemiaNCT04669067
Acute Myeloid L...
TL-895
KRT-232
18 Years - Telios Pharma, Inc.
Repeat Dose Safety Study for Compound to Treat Hematologic CancerNCT00881946
Hematologic Mal...
GSK21110183
18 Years - Accenture
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT03194685
AML, Adult
FF-10101-01
18 Years - Fujifilm Pharmaceuticals U.S.A., Inc.
A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)NCT01305499
Acute Myeloid L...
Entinostat days...
5AC
Entinostat days...
60 Years - Case Comprehensive Cancer Center
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLNCT04913922
Acute Myeloid L...
Azacitidine Inj...
Nivolumab
Relatlimab
18 Years - Ludwig-Maximilians - University of Munich
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT03194685
AML, Adult
FF-10101-01
18 Years - Fujifilm Pharmaceuticals U.S.A., Inc.
Repeat Dose Safety Study for Compound to Treat Hematologic CancerNCT00881946
Hematologic Mal...
GSK21110183
18 Years - Accenture
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesNCT01823198
Accelerated Pha...
Acute Erythroid...
Acute Megakaryo...
Acute Myeloid L...
Acute Myeloid L...
Acute Myeloid L...
Blast Phase Chr...
Blasts Under 20...
Blasts Under 20...
Chronic Myelomo...
High Risk Myelo...
Myelodysplastic...
Recurrent Chron...
Therapy-Related...
Therapy-Related...
Aldesleukin
Allogeneic CD56...
Allogeneic Hema...
Busulfan
Fludarabine Pho...
Laboratory Biom...
Peripheral Bloo...
Pharmacological...
7 Years - 65 YearsM.D. Anderson Cancer Center
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent EngraftmentNCT02099266
Acute Myeloid L...
Acute Lymphobla...
Myelodysplastic...
Hodgkins Lympho...
Non-Hodgkins Ly...
Administration ...
17 Years - 70 YearsUniversity of Kansas Medical Center
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaNCT05396859
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Entrectinib
Laboratory Biom...
18 Years - OHSU Knight Cancer Institute
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerNCT00723099
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 YearsFred Hutchinson Cancer Center
Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid LeukemiaNCT05983172
Acute Myeloid L...
18 Years - National Taiwan University Hospital
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionNCT05010772
Acute Myeloid L...
Decitabine and ...
Enasidenib
Gilteritinib
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive ChemotherapyNCT05249894
Acute Myeloid L...
18 Years - 70 YearsAzienda Ospedaliera Città della Salute e della Scienza di Torino
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AMLNCT06110208
Acute Myeloid L...
CLL1 and CD38 d...
18 Years - 70 Years920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingNCT04128501
Acute Bilineal ...
Acute Biphenoty...
Acute Myeloid L...
Mixed Phenotype...
T Acute Lymphob...
Therapy-Related...
Azacitidine
Venetoclax
18 Years - 75 YearsM.D. Anderson Cancer Center
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid LeukemiaNCT06017258
Refractory Acut...
Relapsed Acute ...
Acute Myeloid L...
Acute Myeloid L...
Acute Myeloid L...
CD371-YSNVZ-IL1...
1 Year - Memorial Sloan Kettering Cancer Center
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell TransplantationNCT00795548
Myelodysplastic...
Acute Myeloid L...
5-Azacitidine
18 Years - Heinrich-Heine University, Duesseldorf
Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years OldNCT02432911
Acute Myeloid L...
CAG regimen (Ac...
low dose cytara...
65 Years - 75 YearsChineseAMS
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesNCT03263637
Relapsed or Ref...
Acute Myeloid L...
Acute Lymphocyt...
Chronic Lymphoc...
High Risk Myelo...
Chronic Myelomo...
Richter's Syndr...
B-cell Non-Hodg...
T-cell Non-Hodg...
Small Lymphocyt...
Multiple Myelom...
AZD4573
18 Years - 130 YearsAstraZeneca
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid LeukemiaNCT04789408
Acute Myeloid L...
Cyclophosphamid...
Fludarabine
KITE-222
18 Years - Gilead Sciences
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute LeukemiaNCT01677949
Acute Myeloid L...
Acute Lymphobla...
Clofarabine
Etoposide
Cyclophosphamid...
allogeneic hema...
- 60 YearsMasonic Cancer Center, University of Minnesota
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic SyndromeNCT01311258
Acute Myeloid L...
Myelodysplastic...
18 Years - University of Rochester
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine HospitalNCT05558943
Acute Myeloid L...
18 Years - Assistance Publique - Hôpitaux de Paris
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesNCT01461538
Acute Lymphoid ...
Acute Myeloid L...
Anemia, Refract...
Solid Tumors
brentuximab ved...
brentuximab ved...
brentuximab ved...
6 Years - Seagen Inc.
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AMLNCT01191801
Acute Myeloid L...
vosaroxin + cyt...
placebo + cytar...
18 Years - Sunesis Pharmaceuticals
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesNCT04156256
Hematologic Mal...
Acute Myeloid L...
Myelodysplastic...
Myeloproliferat...
Chronic Myeloid...
CD123-CD33 cCAR...
- iCell Gene Therapeutics
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaNCT04964505
Acute Myeloid L...
Azacitidine
Uproleselan
Venetoclax
18 Years - University of California, Davis
Natural Killer Cell (CYNK-001) Infusions in Adults With AMLNCT04310592
Leukemia
Leukemia, Myelo...
Leukemia, Myelo...
Neoplasms by Hi...
Neoplasms
Immunosuppressi...
Immunologic Fac...
Physiological E...
Alkylating Agen...
Antimetabolites...
Antiviral Agent...
Analgesics, Non...
Anti-infective ...
Analgesics
Peripheral Nerv...
Hematologic Dis...
Hematologic Neo...
Leukemia in Rem...
Relapsed Adult ...
Refractory AML
CYNK-001
18 Years - 80 YearsCelularity Incorporated
Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)NCT02101983
Acute Myeloid L...
Cytosine Arabin...
55 Years - 65 YearsUniversity of Rochester
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaNCT01238211
Acute Myeloid L...
Acute Myeloid L...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Core Binding Fa...
Secondary Acute...
Therapy-Related...
Cytarabine
Dasatinib
Daunorubicin Hy...
Laboratory Biom...
18 Years - National Cancer Institute (NCI)
Haploidentical Stem Cell Transplantation for Children With Therapy Resistant LeukemiaNCT01025778
Acute Lymphobla...
Acute Myeloid L...
Clofarabine for...
Etoposide for r...
Cyclophosphamid...
Clofarabine in ...
Thiotepa in con...
Melfalan in con...
Haploidentical ...
Donor lymphocyt...
1 Year - 21 YearsLund University Hospital
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaNCT04172844
Acute Myelogeno...
Azacitidine
Venetoclax
Pevonedistat
18 Years - Medical College of Wisconsin
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)NCT04827069
Acute Myeloid L...
Clifutinib Besy...
18 Years - Sunshine Lake Pharma Co., Ltd.
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)NCT06297551
Acute Myeloid L...
Quantification ...
18 Years - Stony Brook University
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantNCT06059391
Acute Lymphobla...
Acute Myeloid L...
Chronic Lymphoc...
Chronic Myeloid...
Hematopoietic a...
Hodgkin Lymphom...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Non-Hodgkin Lym...
Allogeneic Hema...
Biospecimen Col...
Granulocyte Col...
Hematopoietic C...
Multi-peptide C...
Pheresis
Placebo Adminis...
Stem Cell Mobil...
18 Years - City of Hope Medical Center
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their SiblingsNCT04969601
Acute Leukemia
Acute Lymphobla...
Acute Myeloid L...
vaccine COMIRNA...
1 Year - 15 YearsAssistance Publique - Hôpitaux de Paris
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113NCT04070768
Acute Myeloid L...
Gemtuzumab Ozog...
Venetoclax
18 Years - Big Ten Cancer Research Consortium
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeNCT05140811
Acute Myeloid L...
Myelodysplastic...
IMM01
Azacitidine
18 Years - ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell TransplantNCT06197672
Acute Myeloid L...
CD4CAR
18 Years - Indiana University
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and AdolescentsNCT00111345
Myeloid Leukemi...
Anthracyclines
liposomal dauno...
2-CDA
AI
1 Day - 18 YearsUniversity Hospital Muenster
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesNCT01943851
Neoplasms
GSK525762
18 Years - GlaxoSmithKline
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.NCT03350152
Acute Myeloid L...
- Hospices Civils de Lyon
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)NCT00880243
Acute Myeloid L...
GM-CSF
15 Years - 50 YearsAcute Leukemia French Association
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or LymphomaNCT04460235
Vaccine
Streptococcus P...
Acute Myeloid L...
Lymphoma, Non-H...
Prevenar13 Pneu...
18 Years - Poitiers University Hospital
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2NCT03338348
Acute Myeloid L...
Myelodysplastic...
Vosaroxin
Azacitidine
60 Years - University of Ulm
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT05961839
Acute Myeloid L...
High-Risk and V...
SGR-2921
18 Years - Schrödinger, Inc.
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple MyelomaNCT04097301
Acute Myeloid L...
Multiple Myelom...
MLM-CAR44.1 T-c...
1 Year - 75 YearsAGC Biologics S.p.A.
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid CancersNCT00488592
Myelodysplastic...
Acute Myeloid L...
Chronic Myeloid...
WT1:126-134
PR1:169-177 Pep...
GM-CSF (Sargram...
Montanide adjuv...
18 Years - 85 YearsNational Institutes of Health Clinical Center (CC)
Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid LeukemiaNCT03027102
Acute Myeloid L...
DNT cells
18 Years - University Health Network, Toronto
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSNCT04055844
Acute Myeloid L...
Myeloid and Mon...
Myelodysplastic...
Decitabine
Ruxolitinib
Donor Lymphocyt...
12 Years - Masonic Cancer Center, University of Minnesota
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid LeukemiaNCT04980885
Acute Myeloid L...
AK117
Azacitidine
18 Years - Akeso
Removing Transfusion Dependence as a Barrier to Hospice EnrollmentNCT05063591
Hematologic Mal...
Myelodysplastic...
Acute Myeloid L...
Lymphoma
Leukemia
Myeloma
Transfusion sup...
18 Years - Brown University
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic LymphomaNCT03178617
Acute Lymphobla...
Acute Myeloid L...
Lymphoblastic L...
Acute Leukemia
Educational Int...
Educational Int...
Quality-of-Life...
Questionnaire A...
5 Years - City of Hope Medical Center
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesNCT05588154
Myelodysplastic...
18 Years - National Institutes of Health Clinical Center (CC)
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple MyelomaNCT04097301
Acute Myeloid L...
Multiple Myelom...
MLM-CAR44.1 T-c...
1 Year - 75 YearsAGC Biologics S.p.A.
Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid LeukemiaNCT05000801
Acute Myeloid L...
DC vaccine
18 Years - 70 YearsAffiliated Hospital to Academy of Military Medical Sciences
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AMLNCT05703126
Acute Myeloid L...
Cardiotoxicity
Endothelial Dys...
History taking
Anthropometry
Complete blood ...
Biochemical blo...
Coagulogram
Immunoenzymatic...
Stress echocard...
Triplex scannin...
Electrocardiogr...
Ultrasound of t...
Cytogenetic exa...
Cytological exa...
Immunophenotypi...
Determination o...
laser Doppler f...
18 Years - 65 YearsSamara State Medical University
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLNCT03642236
FLT3-ITD Mutati...
Acute Myeloid L...
Brutons Tyrosin...
Ibrutinib
14 Years - 60 YearsNanfang Hospital, Southern Medical University
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)NCT02775903
Leukemia, Myelo...
Myelodysplastic...
Azacitidine
Durvalumab
18 Years - Celgene
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AMLNCT01191957
Acute Myeloid L...
Busulphan plus ...
Busulphan plus ...
40 Years - 65 YearsGruppo Italiano Trapianto di Midollo Osseo
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerNCT05400122
Colorectal Canc...
Hematologic Mal...
Rectum Cancer
Acute Myeloid L...
Myelodysplastic...
Acute Lymphobla...
Chronic Myeloid...
Chronic Lymphoc...
Hodgkin Lymphom...
Non Hodgkin Lym...
Myeloproliferat...
Plasma Cell Mye...
Vactosertib
Fludarabine Pho...
Cyclophosphamid...
IL-2
Natural Killer ...
18 Years - Case Comprehensive Cancer Center
Clinical Study of CWP232291 in Acute Myeloid Leukemia PatientsNCT03055286
Acute Myeloid L...
CWP232291
18 Years - JW Pharmaceutical
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaNCT03009240
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Therapy-Related...
Untreated Adult...
Decitabine
Laboratory Biom...
Pevonedistat
Pharmacological...
18 Years - City of Hope Medical Center
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSNCT03417154
Acute Myeloid L...
Higher Risk Mye...
Nivolumab
Low dose Cyclop...
Low dose Cyclop...
18 Years - Masonic Cancer Center, University of Minnesota
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)NCT02323022
Acute Myeloid L...
IAC regimen
IA regimen
18 Years - 60 YearsThe First Affiliated Hospital of Soochow University
Long-term Outcomes for Acute Myeloid Leukemia PatientsNCT03755856
Acute Myeloid L...
Questionnaire
18 Years - Gruppo Italiano Malattie EMatologiche dell'Adulto
Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96NCT04589728
Acute Myeloid L...
Venetoclax plus...
18 Years - Gruppo Italiano Malattie EMatologiche dell'Adulto
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaNCT05520567
Acute Myeloid L...
FLT3-mutated Ac...
Gilteritinib
Venetoclax
Azacitidine
18 Years - Astellas Pharma Inc
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmNCT06006403
Acute Myeloid L...
Blastic Plasmac...
Relapse Leukemi...
Refractory Leuk...
CD123 targeted ...
18 Years - 75 YearsChongqing Precision Biotech Co., Ltd
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic MalignanciesNCT01622556
Hematologic Mal...
Fludarabine
Busulfan
Thymoglobulin
Total Body Irra...
Umbilical Cord ...
18 Years - 70 YearsUniversity of Virginia
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyNCT00990587
Hematologic Mal...
Acute Lymphocyt...
Chronic Lymphoc...
Myelodysplasia
Acute Myeloid L...
Chronic Myeloge...
Hodgkin's Disea...
Ciclopirox Olam...
18 Years - University Health Network, Toronto
Transfusional Iron Overload Among Leukemia SurvivorsNCT01965171
Acute Lymphocyt...
Acute Myeloid L...
5 Years - St. Jude Children's Research Hospital
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: